VBI-1901 is under clinical development by VBI Vaccines and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VBI-1901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VBI-1901 overview

VBI-1901 is under development for the treatment of recurrent glioblastoma multiforme and medulloblastoma. It is administered intradermally when adjuvanted with GM-CSF and intramuscularly when adjuvanted with the AS01B adjuvant system. The vaccine candidate constitutes a virus-like particle expressing two CMV antigens, glycoprotein B, and pp65. It is developed based on eVLP virus-like particle (VLP) vaccine technology.

VBI Vaccines overview

VBI Vaccines (VBI), a subsidiary of FDS Pharma LLP is a biopharmaceutical company that discovers and develops novel vaccines in the therapeutic areas of immuno-oncology and infectious diseases. The company’s pipeline vaccine candidates include cytomegalovirus; glioblastoma multiforme, and zika virus. It utilizes technologies such as eVLP platform, and thermostable platform to develop the vaccine candidates. VBI offers Sci-B-Vac, a hepatitis B vaccine which consists of surface antigens of hepatitis B virus and is free of any next-generation adjuvant. The company operates through its research facilities located in Ottawa, Canada; and a manufacturing facility in Rehovot, Israel. VBI is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of VBI-1901’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.